MA28335A1 - Agonistes du recepteur (vpac2) du type peptides activant l'adenylate cyclase hypophysaire (pacap) et procedes pharmacologiques d'utilisation de ces agonistes - Google Patents

Agonistes du recepteur (vpac2) du type peptides activant l'adenylate cyclase hypophysaire (pacap) et procedes pharmacologiques d'utilisation de ces agonistes

Info

Publication number
MA28335A1
MA28335A1 MA29206A MA29206A MA28335A1 MA 28335 A1 MA28335 A1 MA 28335A1 MA 29206 A MA29206 A MA 29206A MA 29206 A MA29206 A MA 29206A MA 28335 A1 MA28335 A1 MA 28335A1
Authority
MA
Morocco
Prior art keywords
agonists
vpac2
receptor
hypophysic
pacap
Prior art date
Application number
MA29206A
Other languages
English (en)
French (fr)
Inventor
Kevin Clairmont
Kevin J Lumb
Thomas Buckholz
Arthur I Salhanick
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of MA28335A1 publication Critical patent/MA28335A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
MA29206A 2004-01-27 2006-07-24 Agonistes du recepteur (vpac2) du type peptides activant l'adenylate cyclase hypophysaire (pacap) et procedes pharmacologiques d'utilisation de ces agonistes MA28335A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53955004P 2004-01-27 2004-01-27
US56649904P 2004-04-29 2004-04-29

Publications (1)

Publication Number Publication Date
MA28335A1 true MA28335A1 (fr) 2006-12-01

Family

ID=34830483

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29206A MA28335A1 (fr) 2004-01-27 2006-07-24 Agonistes du recepteur (vpac2) du type peptides activant l'adenylate cyclase hypophysaire (pacap) et procedes pharmacologiques d'utilisation de ces agonistes

Country Status (13)

Country Link
US (1) US20090143283A1 (enExample)
EP (1) EP1713493A4 (enExample)
JP (1) JP2007519739A (enExample)
KR (1) KR20070009554A (enExample)
AU (1) AU2005208911A1 (enExample)
BR (1) BRPI0507177A (enExample)
CA (1) CA2554475A1 (enExample)
EC (1) ECSP066793A (enExample)
IL (1) IL176705A0 (enExample)
MA (1) MA28335A1 (enExample)
NO (1) NO20063801L (enExample)
RU (1) RU2006130691A (enExample)
WO (1) WO2005072385A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2575101A1 (en) * 2004-06-12 2005-12-29 Bayer Pharmaceuticals Corporation Pegylation of vasoactive intestinal peptide (vip)/pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use
EP1896048A4 (en) * 2005-05-06 2010-11-03 Bayer Pharmaceuticals Corp PEPTIDE RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND THEIR PHARMACOLOGICAL METHODS OF USE
KR101057284B1 (ko) 2005-10-26 2011-08-16 일라이 릴리 앤드 캄파니 선택적 ｖｐａｃ２ 수용체 펩티드 작동제
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
CA2983030A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
SG10202109691UA (en) 2016-04-15 2021-10-28 Alder Biopharmaceuticals Inc Anti-pacap antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU656230B2 (en) * 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
DE60039111D1 (de) * 1999-09-28 2008-07-17 Bayer Corp Agonisten des rezeptors 3 (r3) von pituitary adenylate cyclase aktivierendem peptid (pacap) und ihre pharmakologische verwendung
US20050009739A1 (en) * 2002-02-14 2005-01-13 Wei Wang Formulation strategies in stabilizing peptides in organic solvents and in dried states
US7378494B2 (en) * 2002-07-12 2008-05-27 Bayer Healthcare Ag Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonist peptide

Also Published As

Publication number Publication date
EP1713493A2 (en) 2006-10-25
JP2007519739A (ja) 2007-07-19
KR20070009554A (ko) 2007-01-18
WO2005072385A2 (en) 2005-08-11
AU2005208911A1 (en) 2005-08-11
ECSP066793A (enExample) 2006-11-16
IL176705A0 (en) 2006-10-31
CA2554475A1 (en) 2005-08-11
BRPI0507177A (pt) 2007-06-26
EP1713493A4 (en) 2009-06-24
NO20063801L (no) 2006-10-26
WO2005072385A3 (en) 2006-06-08
RU2006130691A (ru) 2008-03-10
US20090143283A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
Larsen et al. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats
Brown et al. Brain peptide regulation of adrenal epinephrine secretion
Dogrukol-Ak et al. Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects
Banks The many lives of leptin
Cabou et al. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity
Ludvik et al. Amylin: history and overview
Bratusch-Marrain et al. Efficacy of pulsatile versus continuous insulin administration on hepatic glucose production and glucose utilization in type I diabetic humans
Deacon et al. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs
CN1487952A (zh) 具有血管活性肠肽的生物学活性的用于治疗肺动脉和小动脉高压的化合物
Ahlborg et al. Metabolic and vascular effects of circulating endothelin-1 during moderately heavy prolonged exercise
Bray Food intake, sympathetic activity, and adrenal steroids
JP2007534613A (ja) レラキシンスーパーファミリーペプチド類似体
EP1976548A1 (en) Vip fragments and methods of use
Yokota et al. PACAP stimulates glucose output from the perfused rat liver
Knigge et al. Involvement of histaminergic neurons in the stress-induced release of pro-opiomelanocortin-derived peptides in rats
Sanfield et al. Epinephrine increases plasma immunoreactive atrial natriuretic hormone levels in humans
Antoniou et al. Differential effects of the neuropeptide galanin on striatal acetylcholine release in anaesthetized and awake rats
Jiang et al. The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies
Ahrén et al. Interaction of vasoactive intestinal peptide (VIP) with cholinergic stimulation of glucagon secretion
WO2005072385A3 (en) Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use
Patil et al. Role of insulin in management of type 2 diabetes mellitus
Gürün et al. Intracerebroventricular choline reverses hypotension induced by acute chemical sympathectomy
Mueller et al. GIP potentiates CCK stimulated pancreatic enzyme secretion: correlation of anatomical structures with the effects of GIP and CCK on amylase secretion
Plamondon et al. Effects of central neuromedin B and related peptides on blood glucose
Kaplan The pituitary gland: a brief history